Based on the earnings conference call transcripts, the key financial metrics for the first quarter are as follows:

1. Global revenues: $892.4 million, up 2.1% from Q1 2016
2. Internal growth: 3.6% excluding the impact of foreign exchange, acquisitions, divestitures, and manufacturing and industrial services
3. Domestic and Canada revenues: $710.8 million, with internal growth of 2.2%
4. International revenues: $181.6 million, with adjusted internal growth of 1.8%
5. Gross profit: $368.7 million, or 41.3% of revenues
6. SG&A (excluding amortization): $198.3 million, or 22.2% of revenues
7. Adjusted income from operations (EBITA): $170.4 million, or 19.1% of revenues
8. Net income attributable to Stericycle: $53.4 million, or $0.62 per share on an as-reported basis and $1.09 when adjusted for acquisition-related expenses and other adjustments
9. Covenant debt to EBITDA ratio: 3.38 at the end of the quarter
10. Cash from operations: $175.3 million as reported, and $197.7 million when adjusted for recall reimbursements and other items
11. Recalls revenue: $125 million to $150 million globally
12. Capital expenditures (CapEx): $33.1 million, or 3.7% of revenues
13. Days Sales Outstanding (DSO): 62 days
14. Unused portion of the revolver: approximately $715 million
15. Repurchased 145,700 shares of mandatory preferred convertible on the open market in the amount of $9.6 million
16. Authorization to purchase 2.9 million shares at the end of the quarter
17. Anticipated interest expense: $100 million to $104 million
18. Expected reduction of debt to approach and possibly be slightly below three times debt to EBITDA by the end of the year
19. Acquisitions: 88% in the US and Canada, and 12% international

Overall, the company experienced growth in revenues, gross profit, and net income, with a focus on cost management, cash generation, and debt reduction through normal operations. Additionally, acquisitions and international expansion continue to be key areas of focus for driving growth and profitability.